The Sensitivity of Cosmogenic Radionuclide Analysis to Soil Bulk Density:Implications for Soil Formation Rates

Improving our knowledge of soil formation is critical so that we can better understand the first-order controls on soil thickness and more effectively inform land-management decisions. Cosmogenic radionuclide analysis has allowed soil scientists to more accurately constrain the rates at which soils form from bedrock. In such analysis, the concentration of an isotope, such as Beryllium-10, is measured from a sample of bedrock. Because this concentration is partly governed by the lowering of the bedrock-soil interface, a cosmogenic depth-profile model can be fitted to infer the bedrock and surface lowering rates compatible with the measured concentrations. Given that the bedrock-soil interface is shielded by soil, the cosmic rays responsible for the in-situ production of the radionuclide are attenuated, with attenuation rates dependent on the density profile of this soil. Many studies have assumed that soil bulk density is either equal to that of the bedrock or constant with depth. The failure to acknowledge the variations in soil bulk density means that cosmogenically derived soil formation rates previously published may be under- or overestimates. Here, we deploy a new model called "CoSOILcal" to a global compilation of cosmogenic analyses of soil formation and, by making use of estimated bulk density profiles, recalculate rates of soil formation to assess the sensitivity to this important parameter. We found that where a soil mantle >0.25 m overlies the soil-bedrock interface, accounting for the soil bulk density profile brings about a significantly slower rate of soil formation than that previously published. Moreover, the impact of using bulk density profiles on cosmogenically derived soil formation rates increases as soil thickens. These findings call into question the accuracy of our existing soil formation knowledge and we suggest that future cosmogenic radionuclide analysis must consider the bulk density profile of the overlying soil. Highlights The effect of heterogeneities in soil bulk density on cosmogenically derived soil formation rates is unknown. Soil formation rates are recalculated using a new model to analyse the effect of density variations. Accounting for density in soils >0.25 m thickness brings about significantly slower soil formation rates. Measuring soil bulk density is essential when cosmogenically deriving soil formation rates

Glaciation and deglaciation of the Stump Cross area, Yorkshire Dales, northern England, determined by terrestrial cosmogenic nuclide (10Be) dating.

Terrestrial cosmogenic nuclide (l0Be) surface-exposure ages are reported for three glacially-transported gritstone boulders and one glacially-scoured exposure of gritstone bedrock in the vicinity of Stump Cross Caverns, North Yorkshire. Although the ages do not form a statistically consistent cluster, three of them nevertheless indicate that the transport and deposition of boulders was by ice of the last (Late Devensian) glaciation. The ages provide evidence for glacier ice at the Wharfe-Nidd interfluve, in contrast to previously held views that these uplands had remained above the level of the last ice sheet. The youngest of the three ages on boulders (-18.5 ka) is taken as the best estimate for déglaciation of the area. This is consistent both with surface-exposure ages from sites elsewhere around the southern margin of the Yorkshire Dales and with uranium-series dated speleothems in Stump Cross Caverns. Together these results reveal that déglaciation of the Dales was most likely well advanced by ~18-16 ka, facilitating the rejuvenation of surface and subsurface karstic processes

Glacier expansion in central Patagonia during the Antarctic Cold Reversal followed by retreat and stabilisation during the Younger Dryas

The spatial-temporal footprint of millennial-scale climate events during the last glacial-interglacial transition can yield insights into the underlying drivers of climate change, but remains poorly resolved in Patagonia. Here, we assess the glacier response to abrupt cold events and palaeolake evolution using geomorphological mapping along with ages and optically stimulated luminescence ages from near Lago Belgrano (47.9° S) on the eastern side of Monte San Lorenzo. The former Belgrano glacier was sustained by a climatically sensitive ice cap, making the site ideal for investigating the glacier response to abrupt cold reversals. Our data reveal an extensive re-advance at 13.1 0.6 ka, consistent with cooling and increased precipitation during the Antarctic Cold Reversal (ACR). Subsequently, ice retreated by at least 10 km and created an ice-dammed proglacial lake in the Belgrano valley. Rapid recession was punctuated by smaller advances/still-stands sufficient to maintain an ice-dam for the palaeolake and deposit a lateral moraine dated at 12.4 0.3 ka during the Younger Dryas (YD). The final withdrawal of glaciers to the mountains allowed the palaeolake to drain and resulted in an Atlantic/Pacific drainage reversal. This marks the final separation of the Patagonian Ice Sheet into the individual ice fields at the YD-Holocene transition. Our data demonstrate the dominant ACR climate signal in central Patagonia, but also reveals a co-occurrence of the northern hemisphere YD signal, albeit of smaller magnitude. The ACR re-advance was primarily climatically controlled, but its relative magnitude was likely a consequence of ice divide migration and ice flow re-routing during the break-up of the Patagonian Ice Sheet

Be‐10 dating of ice‐marginal moraines in the Khumbu Valley, Nepal, Central Himalaya, reveals the response of monsoon‐influenced glaciers to Holocene climate change

The dynamic response of large mountain glaciers to climatic forcing operates over timescales of several centuries and therefore understanding how these glaciers change requires observations of their behavior through the Holocene. We used Be-10 exposure-age dating and geomorphological mapping to constrain the evolution of glaciers in the Khumbu Valley in the Everest region of Nepal. Khumbu and Lobuche Glaciers are surrounded by high-relief lateral and terminal moraines from which seven glacial stages were identified and dated to 7.4 ± 0.2, 5.0 ± 0.3, 3.9 ± 0.1, 2.8 ± 0.2, 1.3 ± 0.1, 0.9 ± 0.02, and 0.6 ± 0.16 ka. These stages correlate to each of the seven latest Holocene regional glacial stages identified across the monsoon-influenced Himalaya, demonstrating that a coherent record of high elevation terrestrial palaeoclimate change can be extracted from dynamic mountain landscapes. The time-constrained moraine complex represents a catchment-wide denudation rate of 0.8–1.4 mm a−1 over the last 8 kyr. The geometry of the ablation area of Khumbu Glacier changed around 4 ka from a broad, shallow ice tongue to become narrower and thicker as restricted by the topographic barrier of the terminal moraine complex

Corrigendum to “The million-year evolution of the glacial trimline in the southernmost Ellsworth Mountains, Antarctica” [Earth and Planetary Science Letters 469 (2017) 42–52]

No abstract available

Seropositivity rates for agents of canine vector-borne diseases in Spain : a multicentre study

Background: Controlling canine vector-borne diseases (CVBD) is a major concern, since some of these diseases are serious zoonoses. This study was designed to determine seropositivity rates in Spain for agents causing the following five CVBD: leishmaniosis (Leishmania infantum: Li), heartworm (Dirofilaria immitis: Di), ehrlichiosis (Ehrlichia canis: Ec), anaplasmosis (Anaplasma phagocytophilum/Anaplasma platys: An) and Lyme disease (Borrelia burgdorferi: Bb). Methods: Anti-An, -Bb, and -Ec antibodies and the Di antigen were determined using the 4DX SNAP® Test (IDEXX Laboratories) and anti-L. infantum (Li) antibodies using the Leishmania SNAP® Test (IDEXX Laboratories) in blood and/or serum samples. Results: Among 1100 dogs examined, overall seropositivity rates were: Li (15.7%), Ec (5%), An (3.1%), Di (1.25%) and Bb (0.4%). While seropositivity towards Bb and Di was similar in all geographic regions, rates were significantly higher in the east of Spain (8.3%) for An, significantly higher in the north (20%) for Ec, and significantly higher in the Southeast (46.6%) and South (27.4%), and significantly lower in the north (0%) for Li. No statistical associations were observed between sex and the CVBD analyzed (p ≥ 0.05) while the following associations with other variables were detected: a higher seropositivity to Ec (40%) and Bb (6.7%) in dogs under one year of age compared with adults (p < 0.05); and a higher seropositivity to An and Li in dogs that lived outdoors versus indoors (p = 0.01; p < 0.001, respectively). Seropositivity rates of 2.1%, 0%, 1.7%, 0.5% and 4.2% were recorded respectively for An, Bb, Ec, Di and Li in dogs with no clinical signs (n = 556) versus 3.8%, 0.6%, 7.5%, 1.8% and 25.9% for those with signs (n = 507) suggestive of a CVBD. Conclusion: The data obtained indicate a risk for dogs in Spain of acquiring any of the five CVBD examined. Veterinarians in the different regions should include these diseases in their differential diagnoses and recommend the use of repellents and other prophylactic measures to prevent disease transmission by arthropod vectors. Public health authorities also need to become more involved in the problem, since some of the CVBD examined here also affect humans

Determination of Specific Electrocatalytic Sites in the Oxidation of Small Molecules on Crystalline Metal Surfaces

The identification of active sites in electrocatalytic reactions is part of the elucidation of mechanisms of catalyzed reactions on solid surfaces. However, this is not an easy task, even for apparently simple reactions, as we sometimes think the oxidation of adsorbed CO is. For surfaces consisting of non-equivalent sites, the recognition of specific active sites must consider the influence that facets, as is the steps/defect on the surface of the catalyst, cause in its neighbors; one has to consider the electrochemical environment under which the “active sites” lie on the surface, meaning that defects/steps on the surface do not partake in chemistry by themselves. In this paper, we outline the recent efforts in understanding the close relationships between site-specific and the overall rate and/or selectivity of electrocatalytic reactions. We analyze hydrogen adsorption/desorption, and electro-oxidation of CO, methanol, and ammonia. The classical topic of asymmetric electrocatalysis on kinked surfaces is also addressed for glucose electro-oxidation. The article takes into account selected existing data combined with our original works.M.J.S.F. is grateful to PNPD/CAPES (Brazil). J.M.F. thanks the MCINN (FEDER, Spain) project-CTQ-2016-76221-P

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402